Overview
Metastatic malignant neoplasms affecting the biliary tract (BTC) represent a challenging clinical scenario, often diagnosed at advanced stages with distant metastases precluding curative surgical resection [PMID:31876990]. BTC encompasses a spectrum of malignancies including intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, gallbladder cancer, distal cholangiocarcinoma, and ampulla of Vater carcinoma. The incidence of these cancers has been rising, necessitating a multifaceted approach to management that includes palliative care, symptom relief, and systemic therapies aimed at improving quality of life (QOL) and survival [PMID:31876990]. Understanding the pathophysiology, epidemiology, clinical presentation, diagnostic approaches, and management strategies is crucial for optimizing patient outcomes in this complex condition.
Pathophysiology
The pathophysiology of metastatic BTC involves intricate mechanisms of tumor progression and spread. Many patients present with distant metastases at the time of diagnosis, often involving the liver, lymph nodes, lungs, brain, and bones, which significantly complicate treatment options [PMID:31876990]. These metastases not only limit the feasibility of curative surgical resection but also contribute to systemic symptoms and organ dysfunction. The obstruction of the biliary tract, particularly in hilar regions, leads to jaundice, pruritus, and other debilitating symptoms that impact both palliative and potentially curative treatment strategies [PMID:39390363]. The progression of disease often follows a pattern where initial local growth transitions into metastatic spread, highlighting the need for early detection and intervention to manage symptoms effectively and prolong survival.
Epidemiology
The epidemiology of BTC reveals a concerning trend of increasing incidence over recent years, driven by factors such as aging populations and improved diagnostic capabilities [PMID:31876990]. Utilizing databases like the Hospital Episode Statistics (HES) in England, studies have provided valuable insights into the utilization patterns of palliative interventions such as percutaneous transhepatic biliary drainage (PTBD) among patients with advanced BTC from 2001 to 2014 [PMID:31980509]. These data underscore the growing burden of advanced BTC and the reliance on palliative measures to manage symptoms and improve QOL. Geographic and demographic variations in incidence and outcomes further emphasize the need for tailored, region-specific management strategies.
Clinical Presentation
Patients with advanced BTC often present with a constellation of symptoms reflecting both local and systemic disease manifestations. Bismuth-Corlette (BC) stage II or higher perihilar cholangiocarcinoma (pCCA) frequently presents with jaundice due to malignant hilar obstruction, significantly impacting both palliative and curative treatment approaches [PMID:39390363]. Other common symptoms include persistent pruritus, cholangitis, elevated bilirubin levels, and abdominal pain, which often prompt urgent interventions such as biliary stenting for symptom relief [PMID:27648439]. Patient-reported outcomes using validated questionnaires like the EORTC QLQ-C30 provide critical insights into the QOL and symptom burden experienced by patients with biliary tract cancers, highlighting the multifaceted impact of the disease on daily functioning and well-being [PMID:22950826]. Metastatic patterns frequently involve the liver, lymph nodes, lungs, brain, and bones, contributing to a diverse array of systemic symptoms that complicate management.
Diagnosis
Diagnosis of metastatic BTC involves a combination of clinical assessment, imaging, and biomarker analysis. Imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI) are pivotal in delineating the extent of primary tumor and metastatic spread, often complemented by the Bismuth–Corlette classification system to assess biliary obstruction severity [PMID:34798836]. Laboratory markers, particularly total serum bilirubin (TSB) levels, play a crucial role in assessing the severity of obstruction and guiding therapeutic decisions. Lower TSB levels prior to major hepatic resection are associated with reduced postoperative mortality, underscoring the importance of effective biliary drainage as a marker for both palliative and curative settings [PMID:39390363]. However, the accuracy of diagnostic data from databases like HES is contingent upon the quality of medical documentation and coding practices, which can introduce variability [PMID:31980509]. Post-procedural changes in bilirubin levels and tumor markers, such as significant decreases following biliary drainage procedures like BBDC placement, indicate effective symptom management and can guide further therapeutic strategies [PMID:32474515].
Management
The management of metastatic BTC is multifaceted, focusing on symptom relief, systemic therapy, and palliative interventions. Endoscopic biliary drainage (EBD) via endoscopic retrograde cholangiopancreatography (ERC) and percutaneous transhepatic biliary drainage (PTBD) are cornerstone interventions for palliating jaundice and other obstructive symptoms [PMID:39390363]. Despite extensive use, there remains no clear consensus on the optimal approach between EBD and PTBD, the type of stent, or the extent of drainage needed, often necessitating individualized patient assessment [PMID:39390363]. Novel techniques, such as the FLA method and modifications to stent placement (e.g., side holes in plastic stents), have shown promise in reducing complications like stent migration and improving procedural success rates [PMID:34798836]. PTBD, while effective, carries significant complication risks, including cholangitis, sepsis, hemorrhage, and stent blockage, necessitating vigilant post-procedural care [PMID:31980509]. According to National Comprehensive Cancer Network (NCCN) guidelines, palliative surgery is generally discouraged in advanced BTC due to high risks and limited benefits, with chemotherapy and radiation therapy being preferred strategies [PMID:31876990]. Gemcitabine combined with cisplatin is widely accepted as a first-line palliative chemotherapy regimen, though longitudinal QOL data across multiple treatment lines remain limited [PMID:22950826]. In second-line settings, regimens like OFF (oxaliplatin, fluorouracil, and folinic acid) have demonstrated survival benefits, though their impact on QOL is less robust compared to first-line therapies [PMID:22950826]. Surgical biliary bypass, particularly in elderly patients, has shown comparable morbidity and mortality rates to younger patients, with potential survival advantages and improved QOL [PMID:19248198].
Complications
Management of metastatic BTC is fraught with potential complications that can significantly impact patient outcomes. Both endoscopic and percutaneous drainage methods offer comparable technical success rates but are not without risks. Complications from PTBD can be as high as 30%, encompassing serious issues such as cholangitis, sepsis, bleeding, and stent blockage, emphasizing the need for meticulous post-procedural monitoring and management [PMID:31980509]. Secondary outcomes from meta-analyses highlight additional concerns like pancreatitis and postpapillotomy bleeding, which are critical in guiding clinical decision-making [PMID:27648439]. In surgical interventions, elderly patients (≥65 years) experience complications such as intraabdominal abscesses, pulmonary atelectasis, and wound infections, though mortality rates remain relatively low [PMID:19248198]. Cancer cell seeding along catheter tracts, particularly in the abdominal wall, represents a serious long-term complication that requires vigilant surveillance and potential surgical intervention [PMID:17368301]. These complications underscore the importance of multidisciplinary care teams in managing these complex cases effectively.
Prognosis & Follow-up
The prognosis for patients with advanced BTC remains challenging despite advancements in treatment modalities. Persistent cholestasis with elevated TSB levels can limit the efficacy of anti-neoplastic therapies and exacerbate symptoms like pruritus and cholangitis, highlighting the critical role of effective biliary drainage in both therapeutic and palliative contexts [PMID:39390363]. Biliary drainage methods, including PTBD and endoscopic stenting, have been shown to improve QOL and potentially extend survival, aligning with previous findings [PMID:31980509]. However, the overall survival times and QOL improvements remain suboptimal, necessitating ongoing research into novel therapeutic approaches [PMID:31876990]. Longitudinal studies focusing on QOL changes across multiple treatment lines are scarce, indicating a gap in understanding long-term patient outcomes and the sustainability of symptom relief [PMID:22950826]. Regular follow-up is essential to monitor disease progression, manage complications, and adjust treatment strategies accordingly, ensuring that patients receive comprehensive care that addresses both physical and psychological well-being.
Key Recommendations
References
1 Drews J, Baar LC, Schmeisl T, Bunde T, Stang A, Reese T et al.. Biliary drainage in palliative and curative intent European patients with hilar cholangiocarcinoma and malignant hilar obstruction: a retrospective single center analysis. BMC gastroenterology 2024. link 2 Zhang H, Li F, Huang J, Huo C, Huang J. Fishing line assisted endoscopic placement of multiple plastic biliary stents for unresectable malignant hilar biliary obstruction: a retrospective study. BMC gastroenterology 2021. link 3 Rees J, Mytton J, Evison F, Mangat KS, Patel P, Trudgill N. The outcomes of biliary drainage by percutaneous transhepatic cholangiography for the palliation of malignant biliary obstruction in England between 2001 and 2014: a retrospective cohort study. BMJ open 2020. link 4 Wang J, Bo X, Nan L, Wang CC, Gao Z, Suo T et al.. Landscape of distant metastasis mode and current chemotherapy efficacy of the advanced biliary tract cancer in the United States, 2010-2016. Cancer medicine 2020. link 5 Moole H, Dharmapuri S, Duvvuri A, Dharmapuri S, Boddireddy R, Moole V et al.. Endoscopic versus Percutaneous Biliary Drainage in Palliation of Advanced Malignant Hilar Obstruction: A Meta-Analysis and Systematic Review. Canadian journal of gastroenterology & hepatology 2016. link 6 Zabernigg A, Giesinger JM, Pall G, Gamper EM, Gattringer K, Wintner LM et al.. Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract. BMC cancer 2012. link 7 Hwang SI, Kim HO, Son BH, Yoo CH, Kim H, Shin JH. Surgical palliation of unresectable pancreatic head cancer in elderly patients. World journal of gastroenterology 2009. link 8 Riaz Q, Khan MR. Status of the palliative care education in surgical postgraduate curriculum - implications for Pakistan. JPMA. The Journal of the Pakistan Medical Association 2021. link 9 Jiao D, Zhou X, Li Z, Bi Y, Zhang Q, Li J et al.. A newly designed biliary brachytherapy drainage catheter for patients with malignant biliary obstruction: A pilot study. Journal of cancer research and therapeutics 2020. link 10 Mizuno T, Ishizaki Y, Komuro Y, Yoshimoto J, Sugo H, Miwa K et al.. Surgical treatment of abdominal wall tumor seeding after percutaneous transhepatic biliary drainage. American journal of surgery 2007. link
10 papers cited of 12 indexed.